Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Trametinib and dabrafenib combination therapy against metastatic melanoma

Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia

Trametinib and dabrafenib combination therapy against metastatic melanoma ( Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia )

Personalised cancer medicine and research: Today’s best practice

Prof José Baselga - Massachusetts General Hospital, Boston, USA

Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )

Putting drugs to work against brain metastases in HER2 positive breast cancer:...

Dr Thomas Bachelot – Centre Leon Berard, Lyon

Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study ( Dr Thomas Bachelot – Centre Leon Berard, Lyon )

Phase I study examining PI 3 kinase inhibitor for various tumours

Dr Pamela Munster – University of California, San Francisco, USA

Phase I study examining PI 3 kinase inhibitor for various tumours ( Dr Pamela Munster – University of California, San Francisco, USA )

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK...

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

A proof-of-concept study of ODM-201 in patients with progressive castration...

Dr Christophe Massard - Institute Gustave Roussy, Paris, France

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer ( Dr Christophe Massard - Institute Gustave Roussy, Paris, France )

Too few women being offered breast-conserving treatment?

Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy

Too few women being offered breast-conserving treatment? ( Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy )

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib...

Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )

Phase I and II trials focus on drug combination slowing development of...

Prof Yossef Yarden - Weizmann Institute of Science, Israel.

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )

Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy

Prof David Ferry - New Cross Hospital, Wolverhampton, UK

Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy ( Prof David Ferry - New Cross Hospital, Wolverhampton, UK )

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Dr Tony Mok - Chinese University of Hong Kong

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )

Sorafenib does not extend overall survival as third or fourth line therapy in...

Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial ( Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain )

More from ecancer